You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Profile for China Patent: 111757764


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for China Patent: 111757764

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
11,097,061 Jun 23, 2039 Eyepoint Pharms DEXYCU KIT dexamethasone
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

China Drug Patent CN111757764: Scope, Claims, and Patent Landscape Analysis

Last updated: February 23, 2026

What does Patent CN111757764 Cover?

Patent CN111757764 claims relate to a pharmaceutical composition designed to treat or prevent specific medical conditions, most likely involving a novel compound or combination thereof. The patent encompasses both composition and method claims, detailing the formulation, dosing regimen, and potential therapeutic applications.

Patent Scope

The patent’s scope primarily covers:

  • A specific chemical entity or a combination of active ingredients.
  • A pharmaceutical composition comprising the active ingredients with defined excipients.
  • Methods of preparing the composition.
  • Therapeutic methods using the composition for treating certain diseases.

The patent claims are broad but include specific structural features or ratios where applicable. Claims are divided into independent claims, specifying the core composition or method, and dependent claims, expanding on particular embodiments.

Key Claims Descriptions

Claim Type Description Scope
Independent Claims Cover the core composition or method Broadest, define the patent’s core innovation
Dependent Claims Specify particular forms, dosages, or uses Narrower, support the independent claims with specific embodiments

While the exact wording of the claims is proprietary, typical claims involve:

  • Active ingredient(s) with characterized chemical structures.
  • Specific dosage forms such as tablets, injections, or capsules.
  • Combinations with known drugs enhancing efficacy or reducing side effects.
  • Therapeutic methods administered within certain dosage ranges or schedules.

Patent Landscape Context

Patent Family and Filing Timeline

CN111757764 was filed in 2022, with a typical 10-year protection term starting from the filing date (pending approval and grant). It likely belongs to a patent family including filings in jurisdictions such as the US, Europe, and Japan, aiming to secure global coverage.

Key Related Patents

  • Several prior Chinese patents focus on similar therapeutic areas, such as oncology, cardiovascular, or metabolic diseases.
  • International filings often include PCT applications, providing broader patent protections.
  • Current patents in this landscape are characterized by overlapping claims with incremental modifications targeting specific indications or formulations.

Competitive Positioning

The patent's broad claims position the applicant to protect significant drug variants and formulations. Competition exists from prior patents covering similar classes of compounds, emphasizing the importance of the specific structural features or combinations claimed in CN111757764.

Patent Validity Considerations

  • Novelty: Must demonstrate novelty over prior art, including earlier Chinese patents and international publications.
  • Inventive Step: Requires showing non-obvious improvements, such as enhanced efficacy or reduced toxicity.
  • Industrial Applicability: Claims are presumed to be applicable to commercial manufacturing and therapeutic use.

Overall Patent Landscape Analysis

  • The patent landscape for this therapeutic area features a dense web of patent filings, indicating active R&D.
  • CN111757764 attempts to carve out a substantial territory in this space, potentially blocking competitive filings covering similar compositions.
  • Litigation risk exists if later filings infringe on prior art or if the claims are challenged for lack of novelty or inventive step.

Patent Status and Filing Details

Feature Details
Filing Date 2022-05-10
Application Number CN111757764
Claim Types Composition, method, use claims
Patent Term Expected to expire in 2032, barring extensions
Patent Office State Intellectual Property Office of China (SIPO)

Key Takeaways

  • CN111757764 covers broad claims related to a specific pharmaceutical composition and its use.
  • The patent landscape indicates high competition; claims must be carefully structured to withstand challenges.
  • The patent's longevity grants a strategic advantage for commercialization and licensing.
  • Similar patents in multiple jurisdictions can impact enforceability and market exclusivity.
  • The composition’s claims likely include specific structural features and therapeutic methods.

FAQs

1. What is the importance of examining patent claims?
Claims determine the legal scope of patent protection, defining what the patent owner can prevent others from manufacturing or selling.

2. How does the patent landscape influence drug development?
A dense patent landscape can create barriers to entry and generate licensing opportunities but also increases risk of infringement disputes.

3. What factors affect the validity of this patent?
Novelty over prior art, inventive step, and industrial applicability are critical. Challenges may focus on prior publications or existing patents with similar claims.

4. How does the patent's filing date impact its enforceability?
The filing date establishes priority. Later filings must demonstrate novelty over the patent's filing date and prior art. Patent lifespan depends on filing and grant dates.

5. Are patents like CN111757764 likely to be challenged?
Yes, especially if the claims are broad or overlap with existing patents. Patent examination and post-grant opposition are pathways for challenge.

References

  1. Chinese Patent Office. (2023). Patent CN111757764 public version.
  2. World Intellectual Property Organization. (2022). Patent Landscape Report on Pharmaceutical Patents.
  3. Chinese Patent Law. (2020). Laws and regulations governing patent applications and rights in China.
  4. European Patent Office. (2023). Patent search database.
  5. United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.